SCHEMBL6323615

SCHEMBL6323615

Nc1onc(-c2ccc(-c3cccc(Cl)c3)o2)c1C(=O)NCCc1cccc(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
HIF1A Q16665 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TP53 P04637 3/20 0.45
RAB9A P51151 5/20 0.44
NPC1 O15118 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
GAA P10253 1/20 0.44
ALDH1A1 P00352 3/20 0.44
THRB P10828 1/20 0.44
HTT P42858 1/20 0.43
LMNA P02545 2/20 0.43
MAPK1 P28482 2/20 0.42
SLC9A1 P19634 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319732 0.95 MAPT (0.63) MAPTHIF1AMEN1KMT2ATP53
SCHEMBL6316426 0.91 MAPT (0.47) MAPTHIF1AMEN1KMT2ARAB9A
SCHEMBL6316611 0.90 RAB9A (0.48) MAPTTP53RAB9ANPC1GAA
SCHEMBL6315795 0.90 CA1 (0.50) MAPTHIF1AMEN1KMT2ATP53
SCHEMBL6321262 0.90 MAPT (0.56) MAPTMEN1KMT2ATP53SMN1; SMN2
SCHEMBL6318116 0.90 MAPT (0.56) MAPTMEN1KMT2ATP53SMN1; SMN2
SCHEMBL6321922 0.89 MAPT (0.50) MAPTMEN1KMT2ATP53SMN1; SMN2
SCHEMBL6322569 0.89 NPC1 (0.48) MAPTHIF1AMEN1KMT2ATP53
SCHEMBL6315988 0.86 ALDH1A1 (0.51) MAPTHIF1AMEN1KMT2ATP53
SCHEMBL6318878 0.86 ALDH1A1 (0.51) MAPTMEN1KMT2ATP53RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 MAPT 281/4885HIF1A 3267/4885MEN1 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.